Overview

Phase IC Study of Safety and PK of SQ109 300mg Daily

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Healthy male and female volunteers will be given SQ109 300mg daily for 14 days to assess the safety and tolerability and pharmacokinetics.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)